The pharmaceutical world is observing a remarkable shift in blood sugar therapy with the arrival of GLP-1 transdermal devices. These patches offer a possibly more user-friendly alternative to injections of GLP-1 receptor agonists, lessening the frequency of daily needle pricks. The approach deliv